Jupiter Wellness announced data from a recent clinical study of NoStingz, its proprietary topical sunscreen formulated to protect users from jellyfish, sea lice, and UVA/UVB rays. Portuguese man-o’-war, a marine hydrozoan closely related to jellyfish, has a powerful sting that has been known to kill humans. The present in vivo study used Portuguese man-o’-war gathered from the Atlantic Ocean near Key West, Florida. 51 trials were conducted testing 3 sunscreen compounds, one of three being NoStingz, against control. In each trial, 4 separate areas of a participant’s arm were treated with the 3 topical sunscreens, while the control area was left bare. Reconstituted MOW tentacle was applied across all four sections. Participants were asked to assess their pain score on a scale of 1-10. The NoStingz area of the participants’ arms had a statistically significant lower pain score than control and both of other sunscreens tested. Application of MOW toxin often resulted in large, raised welts that persisted for days on the control area of the arms, as well as on one or both of the alternative sunscreens tested, while the NoStingz area remained relatively welt-free.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JUPW:
- Jupiter Wellness Reports Positive Efficacy Results from Clinical Study for its NoStingz Topical Jellyfish Protection Sunscreen
- Jupiter Wellness announces temporary postponement of SRM spin-off
- Jupiter Wellness, Inc. Announces Temporary Postponement of Spin-Off and Distribution of Common Stock of SRM Entertainment, Inc.
- Jupiter Wellness Inc trading halted, news pending
- Jupiter Wellness announces payment date for distribution of SRM stock